HAE – Haemonetics Corporation

Haemonetics Corporation

HAE

$59.89

Name : Haemonetics Corporation

Sector : Healthcare

Industry: Medical Devices

Mark. Cap: $2,803,431,168.00

EPSttm : 3.63

Haemonetics Corporation

$59.89

1.05%

$0.62

HAE — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.53

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

0.81

EPS Last/This Y

1.62

EPS This/Next Y

0.36

Price

59.28

Target Price

85.1

Analyst Recom

Performance Q

-27.75

Upside

35.1%

Beta

0.52

Ticker: HAE

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-17	HAE	60.11	0.36	0.09	5519
2026-03-18	HAE	59.53	0.35	999.99	5566
2026-03-19	HAE	58.89	0.36	0.07	5587
2026-03-20	HAE	58.54	0.36	1.38	5588
2026-03-23	HAE	58.46	0.38	0.00	1774
2026-03-24	HAE	56.67	0.37	0.53	1794
2026-03-25	HAE	55.95	0.37	10.00	1811
2026-03-26	HAE	55.5	0.40	0.05	1844
2026-03-27	HAE	54.05	0.39	0.67	1866
2026-03-30	HAE	54.93	0.39	0.00	1867
2026-03-31	HAE	56.33	0.39	0.04	1870
2026-04-01	HAE	56.25	0.38	0.07	1905
2026-04-02	HAE	56.81	0.38	0.06	1909
2026-04-06	HAE	58.46	0.38	0.00	1925
2026-04-07	HAE	59.58	0.37	0.04	1966
2026-04-08	HAE	59.52	0.20	0.33	3441
2026-04-09	HAE	58.39	0.20	7.00	3443
2026-04-10	HAE	57.34	0.21	1.10	3459
2026-04-13	HAE	59.24	0.21	0.00	3484
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-17	HAE	60.08	2.6	32.3	4.95
2026-03-18	HAE	59.53	2.6	29.0	4.95
2026-03-19	HAE	58.93	2.6	28.7	4.95
2026-03-20	HAE	58.54	2.6	29.6	4.95
2026-03-23	HAE	58.47	2.6	30.5	4.95
2026-03-24	HAE	56.66	2.6	24.2	4.95
2026-03-25	HAE	55.92	2.6	28.1	4.95
2026-03-26	HAE	55.53	2.6	29.4	4.95
2026-03-27	HAE	54.08	2.6	25.4	4.95
2026-03-30	HAE	54.94	2.6	34.4	4.95
2026-03-31	HAE	56.31	2.6	36.1	4.95
2026-04-01	HAE	56.24	2.6	30.4	4.95
2026-04-02	HAE	56.83	2.6	33.1	4.95
2026-04-06	HAE	58.46	2.6	36.9	4.95
2026-04-07	HAE	59.58	2.6	34.9	4.95
2026-04-08	HAE	59.53	2.5	30.7	4.95
2026-04-09	HAE	58.42	2.5	26.8	4.95
2026-04-10	HAE	57.32	2.5	26.8	4.95
2026-04-13	HAE	59.28	2.5	38.1	4.95
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-17	HAE	0.21	-5.55	5.91
2026-03-18	HAE	0.21	-5.55	5.91
2026-03-19	HAE	0.21	-5.55	5.91
2026-03-20	HAE	0.21	-5.55	5.91
2026-03-23	HAE	0.21	-5.53	5.91
2026-03-24	HAE	0.21	-5.53	5.91
2026-03-25	HAE	0.21	-5.53	4.16
2026-03-26	HAE	0.21	-5.53	4.16
2026-03-27	HAE	0.21	-5.53	4.16
2026-03-30	HAE	0.21	-5.53	4.16
2026-03-31	HAE	0.21	-5.53	4.16
2026-04-01	HAE	0.21	-5.53	4.16
2026-04-02	HAE	0.21	-5.53	4.16
2026-04-06	HAE	0.21	-5.53	4.16
2026-04-07	HAE	0.21	-5.53	4.16
2026-04-08	HAE	0.21	-5.53	4.16
2026-04-09	HAE	0.21	-5.53	4.16
2026-04-10	HAE	0.21	-5.53	4.16
2026-04-13	HAE	0.21	-5.54	4.53
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.36

Avg. EPS Est. Current Quarter

1.27

Avg. EPS Est. Next Quarter

1.17

Insider Transactions

0.21

Institutional Transactions

-5.54

Beta

0.52

Average Sales Estimate Current Quarter

337

Average Sales Estimate Next Quarter

332

Fair Value

72.88

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

50.6

Max Drawdown 5-Year %

-63.1

Target Price

85.1

P/E

16.29

Forward P/E

11.2

PEG

1.25

P/S

2.09

P/B

3.05

P/Free Cash Flow

8.94

EPS

3.64

Average EPS Est. Cur. Y

4.95

EPS Next Y. (Est.)

5.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.31

Relative Volume

0.41

Return on Equity vs Sector %

-8.1

Return on Equity vs Industry %

7.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

38.1

◆ HAE Healthcare

$59.27

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

11/25

Volume

11/15

Valuation

20/20

TP/AR

1/10

Options

6/10

RSI

51.1

Range 1M

72.3%

Sup Dist

4.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

10/30

Estimates

6/20

Inst/Vol

0/15

Options

8/10

EPS Yr

8.2%

EPS NY

52W%

29.9%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +64.2% upside

Quality

13/30

Valuation

23/30

Growth

7/25

Stability

4/10

LT Trend

1/5

Upside

+64.2%

Quality

MoS

23%

Haemonetics Corporation

Sector: Healthcare

Industry: Medical Devices

Employees: 3023

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE

Latest News

—

Caricamento notizie per HAE…

stock quote shares HAE – Haemonetics Corporation Stock Price stock today

news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch HAE – Haemonetics Corporation yahoo finance google finance

stock history HAE – Haemonetics Corporation invest stock market

stock prices HAE premarket after hours

ticker HAE fair value insiders trading

HAE – Haemonetics Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: HAE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y